Masso Torrence Wealth Management Inc. Acquires 5,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Masso Torrence Wealth Management Inc. lifted its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 16.7% in the first quarter, Holdings Channel.com reports. The fund owned 35,000 shares of the company’s stock after purchasing an additional 5,000 shares during the quarter. Masso Torrence Wealth Management Inc.’s holdings in Corvus Pharmaceuticals were worth $111,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. RTW Investments LP bought a new position in Corvus Pharmaceuticals during the 4th quarter valued at about $14,335,000. Vivo Capital LLC lifted its holdings in Corvus Pharmaceuticals by 49.2% during the 4th quarter. Vivo Capital LLC now owns 2,234,566 shares of the company’s stock valued at $11,955,000 after purchasing an additional 737,298 shares during the last quarter. Foresite Capital Management VI LLC bought a new position in Corvus Pharmaceuticals during the 4th quarter valued at about $8,460,000. Deerfield Management Company L.P. Series C bought a new position in Corvus Pharmaceuticals during the 4th quarter valued at about $5,350,000. Finally, Geode Capital Management LLC lifted its holdings in Corvus Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock valued at $3,034,000 after purchasing an additional 3,854 shares during the last quarter. 46.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CRVS has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 20th. Oppenheimer reissued an “outperform” rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday, May 9th. Finally, Mizuho set a $11.00 target price on shares of Corvus Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Corvus Pharmaceuticals Trading Up 0.8%

Shares of CRVS stock opened at $3.96 on Friday. Corvus Pharmaceuticals, Inc. has a 1 year low of $1.75 and a 1 year high of $10.00. The firm’s 50 day moving average is $3.71 and its 200-day moving average is $4.46. The firm has a market capitalization of $269.95 million, a price-to-earnings ratio of -4.04 and a beta of 0.57.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). On average, equities research analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.